New bicyclam-GalCer analogue conjugates: Synthesis and in vitro anti-HIV activity

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 2, 2004, Pages 495-498

  Daoudi, Jean Michel ^a   Greiner, Jacques ^a   Aubertin, Anne Marie ^b   Vierling, Pierre ^a  

^a CNRS   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

AMD3100; CXCR4; Galactosylceramide; HIV

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ANTIVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GALACTOSYLCERAMIDE; GALCER;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; DRUG CONJUGATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0347360255     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.10.036     Document Type: Article

References (35)

1. Berger E.A., Murphy P.M., Farber J.M. Annu. Rev. Immunol. 17:1999;657.
2. De Clerq E. Med. Res. Rev. 22:2002;531. and references cited therein.
3. De Clercq E. Mol. Pharmacol. 57:2000;833.
4. (a) Doms R.W., Moore J.P. J. Cell Biol. 151:2000;F9 (b) Pozniak A.J. HIV Ther. 6:2001;91 (c) LaBranche C.C., Galasso G., Moore J.P., Bolognesi D.P., Hirsch M.S., Hammer S.M. Antiv. Res. 50:2001;95 (d) . see also Fujii N., Nakashima H., Tamamura H. Exp. Opin. Investig. Drugs. 12:2003;185. for other CXCR4 antagonists.
5. (a) Doms R.W., Moore J.P. J. Cell Biol. 151:2000;F9 (b) Pozniak A.J. HIV Ther. 6:2001;91 (c) LaBranche C.C., Galasso G., Moore J.P., Bolognesi D.P., Hirsch M.S., Hammer S.M. Antiv. Res. 50:2001;95 (d) . see also Fujii N., Nakashima H., Tamamura H. Exp. Opin. Investig. Drugs. 12:2003;185. for other CXCR4 antagonists.
6. (a) Doms R.W., Moore J.P. J. Cell Biol. 151:2000;F9 (b) Pozniak A.J. HIV Ther. 6:2001;91 (c) LaBranche C.C., Galasso G., Moore J.P., Bolognesi D.P., Hirsch M.S., Hammer S.M. Antiv. Res. 50:2001;95 (d) . see also Fujii N., Nakashima H., Tamamura H. Exp. Opin. Investig. Drugs. 12:2003;185. for other CXCR4 antagonists.
7. (a) Doms R.W., Moore J.P. J. Cell Biol. 151:2000;F9 (b) Pozniak A.J. HIV Ther. 6:2001;91 (c) LaBranche C.C., Galasso G., Moore J.P., Bolognesi D.P., Hirsch M.S., Hammer S.M. Antiv. Res. 50:2001;95 (d) . see also Fujii N., Nakashima H., Tamamura H. Exp. Opin. Investig. Drugs. 12:2003;185. for other CXCR4 antagonists.
8. Yahi N., Sabatier J.M., Nickel P., Mabrouk K., Gonzalez-Scarano F., Fantini J. J. Biol. Chem. 269:1994;24349. and references cited therein.
9. (a) Alfsen A., Iniguez P., Bouguyon E., Bomsel M. J. Immunol. 166:2001;6257
10. (b) Alfsen A., Bomsel M. J. Biol. Chem. 277:2002;25649. and 2003, 278, 5490.
11. (a) Campbell S.M., Crowe S.M., Mak J. J. Clin. Virol. 22:2001;217
12. (b) Raulin J. Prog. Lipid Res. 41:2002;27 (c) Fantini, J.; Garmy, N.; Mahfoud, R.; Yahi, N. Exp. Rev. Mol. Med. 2002, http://www.expertreviews.org/ 02005392 h.htm .
13. (a) Faroux-Corlay, B.; Clary, L.; Gadras, C.; Hammache, D.; Greiner, J.; Santaella, C.; Aubertin, A. M.; Vierling, P.; Fantini, J. Carbohydr. Res. 2000, 327, 223, and references therein.
14. (b) Conboy J.C., McReynolds K.D., Gervay-Hague J., Saavedra S.S. Angew. Chem., Int. Ed. 39:2000;2882
15. (c) Mahfoud R., Mylvaganam M., Lingwood C.A., Fantini J.J. Lipid Res. 43:2002;1670
16. (d) Villard R., Hammache D., Delapierre G., Fotiadu F., Buono G., Fantini J. Chem. Bio. Chem. 3:2002;517
17. (e) Gu Y., LaBell R., O'Brien D.F., Saavedra S.S. Angew. Chem., Int. Ed. 40:2001;2320. and 2947
18. (f) McReynolds K.D., Bhat A., Conboy J.C., Saavedra S.S., Gervay-Hague J. Bioorg. Med. Chem. 10:2002;625
19. (g) Conboy J.C., McReynolds K.D., Gervay-Hague J., Saavedra S.S. J. Am. Chem. Soc. 124:2002;968.
20. Dessolin J., Galea P., Vlieghe P., Chermann J.C., Kraus J.L. J. Med. Chem. 42:1999;229. and references cited therein.
21. (a) Tamamura H., Omagari A., Hiramatsu K., Kanamoto T., Gotoh K., Kanbara K., Yamamoto N., Nakashima H., Otaka A., Fujii N. Bioorg. Med. Chem. 9:2001;2179
22. (b) Tamamura H., Ishihara T., Oyake H., Imai M., Otaka A., Ibuka T., Arakaki R., Nakashima H., Murakami T., Waki M., Matsumoto A., Yamamoto N., Fujii N. J. Chem. Soc., Perkin Trans. 1. 1998;495.
23. Vlieghe P., Clerc T., Pannecouque C., Witvrouw M., De Clercq E., Salles J.P., Kraus J.L. J. Med. Chem. 45:2002;1275.
24. (a) Matsumoto H., Matsuda T., Nakata S., Mitoguchi T., Kimura T., Hayashi Y., Kiso Y. Bioorg. Med. Chem. 9:2001;417
25. (b) Matsumoto H., Kimura T., Hamawaki T., Kumagai A., Goto T., Sano K., Hayashi Y., Kiso Y. Bioorg. Med. Chem. 9:2001;1589
26. (c) Van Calenbergh S., Nair V. Nucleosides Nucleotides. 18:1999;737
27. (d) Camplo M., Niddam V., Barthelemy P., Faury P., Mourier N., Simon V., Charvet A.S., Trabaud C., Graciet J.C., Chermann J.C., Kraus J.L. Eur. J. Med. Chem. 30:1995;789
28. (e) Mourier N., Trabaud C., Graciet J.C., Simon V., Niddam V., Faury P., Charvet A.S., Camplo M., Chermann J.C., Kraus J.L. Nucleosides Nucleotides. 14:1995;1393.
29. (a) Boitrel B., Andrioletti B., Lachkar M., Guilard R. Tetrahedron Lett. 36:1995;4995
30. (b) Fabbrizzi L., Gatti F., Pallavicini P., Zambarbieri E. Chem.-Eur. J. 5:1999;682.
31. 2+Na=653.4).
32. 50) was derived from the computer-generated median effect plot of the dose-effect data.
33. (a) Moog C., Wick A., Le Ber P., Kirn A., Aubertin A.M. Antivir. Res. 24:1994;275
34. (b) Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. J. Virol. Meth. 20:1988;309
35. (c) Genu-Dellac C., Gosselin G., Puech F., Henry J.C., Aubertin A.M., Aubert G., Kirn A., Imbach J.L. Nucleosides Nucleotides. 10:1991;1345.